Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients With Previously Untreated Chronic Lymphocytic Leukemia

NCT05963074 is registered in ClinicalTrials.gov with Janssen Research & Development, LLC as lead sponsor.

NCT NCT05963074
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05963074 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients With Previously Untreated Chronic Lymphocytic Leukemia
Lead sponsor
Janssen Research & Development, LLC
Phase
Phase 2
Overall status
Active, not recruiting
Start date
May 30, 2024
Completion date
March 19, 2029
Enrollment
333 (actual)
Sites
74

Conditions

As the registry lists them; a condition with its own page is linked.

leukemia, lymphocytic, chronic, b-cell, small lymphocytic lymphoma